DrugPatentWatch Database Preview

Details for Patent: 7,091,208

« Back to Dashboard

Which drugs does patent 7,091,208 protect, and when does it expire?

Patent 7,091,208 protects XELJANZ XR and XELJANZ and is included in two NDAs.

This patent has seventy-five patent family members in fifty-two countries.

Summary for Patent: 7,091,208

Title:	Pyrrolo[2,3-D]pyrimidine compounds
Abstract:	A compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Inventor(s):	Blumenkopf; Todd A. (Old Lyme, CT), Flanagan; Mark E. (Gales Ferry, CT), Munchhof; Michael J. (Salem, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	11/211,217
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,091,208
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,091,208

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016		RX	Yes	Yes						TREATMENT OF RHEUMATOID ARTHRITIS
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012		RX	Yes	No						TREATMENT OF RHEUMATOID ARTHRITIS

International Family Members for US Patent 7,091,208

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	1905
Argentina	026534
Austria	257157
Austria	380031